Public Health, Public Trust and Lobbying
- 1 June 2007
- journal article
- research article
- Published by Taylor & Francis in American Journal of Bioethics
- Vol. 7 (6) , 4-7
- https://doi.org/10.1080/15265160701429599
Abstract
Each year, infection with Human Papillomavirus (HPV) leads to millions of abnormal Pap smears and thousands of cases of cervical cancer in the US. Throughout the developing world, where Pap smears are less common, HPV is a leading cause of cancer death among women. So when the international pharmaceutical giant Merck developed a vaccine that could prevent infection with several key strains of HPV, the public health community was anxious to celebrate a major advance. But then marketing and lobbying got in the way. Merck chose to pursue an aggressive lobbying campaign, trying to make its new vaccine mandatory for young girls. The campaign stoked public mistrust about how vaccines come to be mandated, and now it's not just Merck's public image that has taken a hit. The public health community has also been affected. What is the lesson to be learned from this story? Public health communication relies on public trust.Keywords
This publication has 6 references indexed in Scilit:
- Invasive Pneumococcal Disease Caused by Nonvaccine Serotypes Among Alaska Native Children With High Levels of 7-Valent Pneumococcal Conjugate Vaccine CoverageJAMA, 2007
- Will Widespread Human Papillomavirus Prophylactic Vaccination Change Sexual Practices of Adolescent and Young Adult Women in America?Obstetrics & Gynecology, 2006
- Markets and Public Health: Pushing and Pulling Vaccines into ProductionAmerican Journal of Bioethics, 2006
- Risk and Trust in Public Health: A Cautionary TaleAmerican Journal of Bioethics, 2006
- Why Sole-Supplier Vaccine Markets May Be Here To StayHealth Affairs, 2005
- The Left Hemisphere's Role in Hypothesis FormationJournal of Neuroscience, 2000